Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 06 2024 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 6, 2024
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’
overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share
repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council
of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and to meet obligations
arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024
and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
Novo
Nordisk A/S Investor
Relations | Novo
Allé 1 2880
Bagsværd Denmark | Telephone: +45
4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | Company
announcement No 38 / 2024 |
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
|
|
Ida Melvold Gjøsund +45 3077 5649
idmg@novonordisk.com |
|
Novo
Nordisk A/S Investor
Relations | Novo
Allé 1 2880
Bagsværd Denmark | Telephone: +45
4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | Company
announcement No 38 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 6, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From May 2023 to May 2024